64 related articles for article (PubMed ID: 34336233)
21. Systematic Review of Systemic Therapies and Therapeutic Combinations with Local Treatments for High-risk Localized Prostate Cancer.
Tosco L; Briganti A; D'amico AV; Eastham J; Eisenberger M; Gleave M; Haustermans K; Logothetis CJ; Saad F; Sweeney C; Taplin ME; Fizazi K
Eur Urol; 2019 Jan; 75(1):44-60. PubMed ID: 30286948
[TBL] [Abstract][Full Text] [Related]
22. Androgen-targeted therapy in men with prostate cancer: evolving practice and future considerations.
Crawford ED; Heidenreich A; Lawrentschuk N; Tombal B; Pompeo ACL; Mendoza-Valdes A; Miller K; Debruyne FMJ; Klotz L
Prostate Cancer Prostatic Dis; 2019 Mar; 22(1):24-38. PubMed ID: 30131604
[TBL] [Abstract][Full Text] [Related]
23. Contemporary role of postoperative radiotherapy for prostate cancer.
Dal Pra A; Abramowitz MC; Stoyanova R; Pollack A
Transl Androl Urol; 2018 Jun; 7(3):399-413. PubMed ID: 30050800
[TBL] [Abstract][Full Text] [Related]
24. Testosterone suppression in the treatment of recurrent or metastatic prostate cancer - A Canadian consensus statement.
Klotz L; Shayegan B; Guillemette C; Collins LL; Gotto G; Guérette D; Jammal MP; Pickles T; Richard PO; Saad F
Can Urol Assoc J; 2018 Feb; 12(2):30-37. PubMed ID: 29680011
[TBL] [Abstract][Full Text] [Related]
25. National trends in management of localized prostate cancer: A population based analysis 2004-2013.
Chen J; Oromendia C; Halpern JA; Ballman KV
Prostate; 2018 May; 78(7):512-520. PubMed ID: 29542178
[TBL] [Abstract][Full Text] [Related]
26. Adherence to the European Association of Urology Guidelines: A National Survey among Italian Urologists.
Cacciamani G; Artibani W; Briganti A; N'Dow J
Urol Int; 2018; 100(2):139-145. PubMed ID: 29339653
[TBL] [Abstract][Full Text] [Related]
27. Clinical pathway improves implementation of evidence-based strategies for the management of androgen deprivation therapy-induced side effects in men with prostate cancer.
Bultijnck R; Van de Caveye I; Rammant E; Everaert S; Lumen N; Decaestecker K; Fonteyne V; Deforche B; Ost P
BJU Int; 2018 Apr; 121(4):610-618. PubMed ID: 29194928
[TBL] [Abstract][Full Text] [Related]
28. Practice Patterns Compared with Evidence-based Strategies for the Management of Androgen Deprivation Therapy-Induced Side Effects in Prostate Cancer Patients: Results of a European Web-based Survey.
Bultijnck R; Surcel C; Ploussard G; Briganti A; De Visschere P; Fütterer J; Ghadjar P; Giannarini G; Isbarn H; Massard C; Sooriakumaran P; Valerio M; van den Bergh R; Ost P
Eur Urol Focus; 2016 Dec; 2(5):514-521. PubMed ID: 28723517
[TBL] [Abstract][Full Text] [Related]
29. Efficacy of Testosterone Suppression with Sustained-Release Triptorelin in Advanced Prostate Cancer.
Breul J; Lundström E; Purcea D; Venetz WP; Cabri P; Dutailly P; Goldfischer ER
Adv Ther; 2017 Feb; 34(2):513-523. PubMed ID: 28028737
[TBL] [Abstract][Full Text] [Related]
30. Luteinizing Hormone-Releasing Hormone Agonists are Superior to Subcapsular Orchiectomy in Lowering Testosterone Levels of Men with Prostate Cancer: Results from a Randomized Clinical Trial.
Østergren PB; Kistorp C; Fode M; Henderson J; Bennedbæk FN; Faber J; Sønksen J
J Urol; 2017 Jun; 197(6):1441-1447. PubMed ID: 27939836
[TBL] [Abstract][Full Text] [Related]
31. International survey of androgen deprivation therapy (ADT) for non-metastatic prostate cancer in 19 countries.
Liede A; Hallett DC; Hope K; Graham A; Arellano J; Shahinian VB
ESMO Open; 2016; 1(2):e000040. PubMed ID: 27843596
[TBL] [Abstract][Full Text] [Related]
32. Patterns of prescription and adherence to European Association of Urology guidelines on androgen deprivation therapy in prostate cancer: an Italian multicentre cross-sectional analysis from the Choosing Treatment for Prostate Cancer (CHOICE) study.
Morgia G; Russo GI; Tubaro A; Bortolus R; Randone D; Gabriele P; Trippa F; Zattoni F; Porena M; Mirone V; Serni S; Del Nero A; Lay G; Ricardi U; Rocco F; Terrone C; Pagliarulo A; Ludovico G; Vespasiani G; Brausi M; Simeone C; Novella G; Carmignani G; Leonardi R; Pinnarò P; De Paula U; Corvò R; Tenaglia R; Siracusano S; Mantini G; Gontero P; Savoca G; Ficarra V;
BJU Int; 2016 Jun; 117(6):867-73. PubMed ID: 26332130
[TBL] [Abstract][Full Text] [Related]
33. EAU guidelines on prostate cancer. Part II: Treatment of advanced, relapsing, and castration-resistant prostate cancer.
Heidenreich A; Bastian PJ; Bellmunt J; Bolla M; Joniau S; van der Kwast T; Mason M; Matveev V; Wiegel T; Zattoni F; Mottet N;
Eur Urol; 2014 Feb; 65(2):467-79. PubMed ID: 24321502
[TBL] [Abstract][Full Text] [Related]
34. Contemporary role of androgen deprivation therapy for prostate cancer.
Pagliarulo V; Bracarda S; Eisenberger MA; Mottet N; Schröder FH; Sternberg CN; Studer UE
Eur Urol; 2012 Jan; 61(1):11-25. PubMed ID: 21871711
[TBL] [Abstract][Full Text] [Related]
35. Prostate cancer in Spain: from guidelines to clinical practice.
Alcaraz A; Burgos FJ; Cózar JM; Gómez-Veiga F; Morote J; Solsona E; Unda M; Carballido J
BJU Int; 2011 Jul; 108(1):61-6. PubMed ID: 21223474
[TBL] [Abstract][Full Text] [Related]
36. Characteristics of urologists predict the use of androgen deprivation therapy for prostate cancer.
Shahinian VB; Kuo YF; Freeman JL; Orihuela E; Goodwin JS
J Clin Oncol; 2007 Dec; 25(34):5359-65. PubMed ID: 18048816
[TBL] [Abstract][Full Text] [Related]
37. Androgen deprivation therapy in the treatment of advanced prostate cancer.
Perlmutter MA; Lepor H
Rev Urol; 2007; 9 Suppl 1(Suppl 1):S3-8. PubMed ID: 17387371
[TBL] [Abstract][Full Text] [Related]
38. Determinants of androgen deprivation therapy use for prostate cancer: role of the urologist.
Shahinian VB; Kuo YF; Freeman JL; Goodwin JS
J Natl Cancer Inst; 2006 Jun; 98(12):839-45. PubMed ID: 16788157
[TBL] [Abstract][Full Text] [Related]
39. Androgen-deprivation therapy as primary treatment for localized prostate cancer: data from Cancer of the Prostate Strategic Urologic Research Endeavor (CaPSURE).
Kawakami J; Cowan JE; Elkin EP; Latini DM; DuChane J; Carroll PR;
Cancer; 2006 Apr; 106(8):1708-14. PubMed ID: 16544313
[TBL] [Abstract][Full Text] [Related]
40. National practice patterns and time trends in androgen ablation for localized prostate cancer.
Cooperberg MR; Grossfeld GD; Lubeck DP; Carroll PR
J Natl Cancer Inst; 2003 Jul; 95(13):981-9. PubMed ID: 12837834
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
